Transplantation of highly purified CD34+Thy-I+ hematopoietic stem cells in patients with recurrent indolent non-hodgkin's lymphoma

Biology of Blood and Marrow Transplantation

Volumn 7, Issue 12, 2001, Pages 680-687

  Vose, Julie M ^a   Bierman, Philip J ^a   Lynch, James C ^a   Atkinson, Kerry ^a   Juttner, Christopher ^a   Hanania, Elie ^a   Bociek, Gregory ^a   Armitage, James O ^a  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

Autologous stem cell transplantation; Hematopoietic stem cells; High dose chemotherapy; Mantle cell lymphoma; Non Hodgkin's lymphoma

Indexed keywords

ANTINEOPLASTIC AGENT; CARMUSTINE; CD34 ANTIGEN; CYCLOPHOSPHAMIDE; CYTARABINE; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; THY 1 ANTIGEN; BIOLOGICAL MARKER;

ADULT; ANTIGEN PURIFICATION; APHERESIS; ARTICLE; AUTOTRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER GROWTH; CELL SELECTION; CELL SORTER; CLINICAL ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEATH; DRUG MEGADOSE; ERYTHROCYTE TRANSFUSION; FEMALE; FLOW CYTOMETRY; FOLLOW UP; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HIGH RISK PATIENT; HUMAN; INFLUENZA; LONG TERM CARE; MALE; MANTLE CELL LYMPHOMA; NEUTROPHIL; NONHODGKIN LYMPHOMA; OUTCOMES RESEARCH; PERIPHERAL BLOOD STEM CELL; PILOT STUDY; PNEUMOCYSTIS PNEUMONIA; PNEUMONIA; RECURRENT CANCER; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; STEM CELL MOBILIZATION; SURVIVAL RATE; THROMBOCYTE TRANSFUSION; TREATMENT OUTCOME; VIRUS INFECTION; CELL COUNT; CELL SEPARATION; COMPARATIVE STUDY; CYTOLOGY; FEASIBILITY STUDY; GRAFT SURVIVAL; GROWTH, DEVELOPMENT AND AGING; HEMATOPOIETIC STEM CELL; IMMUNE SYSTEM; IMMUNOLOGY; METHODOLOGY; MIDDLE AGED; MINIMAL RESIDUAL DISEASE; PHASE 1 CLINICAL TRIAL; SALVAGE THERAPY; SURVIVAL;

ADULT; ANTIGENS, CD34; ANTIGENS, THY-1; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOLOGICAL MARKERS; CELL COUNT; CELL SEPARATION; COHORT STUDIES; FEASIBILITY STUDIES; FEMALE; FLOW CYTOMETRY; GRAFT SURVIVAL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMATOPOIETIC STEM CELLS; HUMANS; IMMUNE SYSTEM; LYMPHOMA, MANTLE-CELL; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; NEOPLASM, RESIDUAL; SALVAGE THERAPY; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 0035544032     PISSN: 10838791     EISSN: None     Source Type: Journal    
DOI: 10.1053/bbmt.2001.v7.pm11787531     Document Type: Article

References (30)

1. Treatment approaches to the low-grade lymphomas
2. The low-grade non-Hodgkin's lymphomas: Challenges and opportunities opportunities
3. Sequential high-dose therapy with peripheral-blood progenitor-cell support in low-grade non-Hodgkin's lymphoma
4. Myeloablative therapy with autologous bone marrow transplantation as consolidation therapy for follicular lymphoma
5. High-dose therapy with autologous hematopoietic rescue for follicular low-grade non-Hodgkin's lymphoma
6. Immunologic purging of marrow assessed by PCR before autologous bone marrow transplantation for B-cell lymphoma
7. Autologous hematopoietic stem cell transplantion for mantle cell lymphoma
8. Randomized trial of filgrastim-mobilized peripheral blood progenitor cell transplantation versus autologous bone-marrow transplantation in lymphoma patients
9. Effect of peripheral blood progenitor cells mobilized by filgrastim (G-CSF) on platelet recovery after high-dose chemotherapy
10. Peripheral blood progenitor cell mobilization using stem cell factor in combination with filgrastim in breast cancer patients
11. Effect of CD34+ peripheral blood progenitor cell dose on hematopoietic recovery
12. Antigenic analysis of hematopoiesis. III. A hematopoietic progenitor cell surface antigen defined by a monoclonal antibody raised against KG-1a cells
13. Autologous transplantion of mobilized peripheral blood CD34+ cells selected by immunomagnetic procedures in patients with multiple myeloma
14. Engraftment and molecular monitoring of CD34+ peripheral-blood stem-cell transplants for follicular lymphoma: A pilot study
15. Optimizing the CD34+ and CD34+ Thy1+ stem cell content of peripheral blood collections
16. Enrichment of human hematopoietic stem cell activity in the CD34+Thy-1+Lin- subpopulation from mobilized peripheral blood
17. Identification of CD34+ subsets after glycoprotease selection: Engraftment of CD34+ Thy-1+Lin- stem cells in fetal sheep
18. Isolation of a candidate human hematopoietic stem-cell population
19. Collection, tumor contamination, and engraftment kinetics of highly purified hematopoietic progenitor cells to support high dose therapy in multiple myeloma
20. Real-time t(11;14) and t(14;18) PCR assays provide sensitive and quantitative assessments of minimal residual disease (MRD)
21. Improved quantitation of minimal residual disease in multiple myeloma using real-time polymerase chain reaction and plasmid-DNA complementarity determining region III standards
22. Nonparametric estimation from incomplete observations
23. Regression model and life-tables
24. High-dose therapy with autologous hematopoietic rescue for follicular low-grade non-Hodgkin's lymphoma
25. Immune dysfunction despite high levels of immunoregulatory cytokine gene expression in autologous peripheral blood stem cell transplanted non-Hodgkin's lymphoma patients
26. Multicenter phase III trial to evaluate CD34+ selected versus unselected autologous peripheral blood progenitor cell transplantation in multiple myeloma
27. Transplantation of highly purified CD34+Thy-1+ hematopoietic stem cells in patients with metastatic breast cancer
28. Rapid and sustained hematopoietic recovery in lethally irradiated mice transplanted with purified Thy-1.1lo Lin-Sca-1+ hematopoietic stem cells
29. Transplantation with selected autologous peripheral blood CD34+ Thy1+ hematopoietic stem cells (HSCs) in multiple myeloma: Impact of HSC dose on engraftment, safety, and immune reconstitution
30. Increased incidence of cytomegalovirus disease after autologous CD34-selected peripheral blood stem cell transplantation